Randomized clinical trials – modern science’s favorite tool – are very rare in fertility research in part because the patient is footing the bill. No one will pay for treatment knowing there is a good chance they will be in a placebo group, according to an opinion printed in the journal Reproductive Sciences.
Strong science today is often based on repeatable double-blind experiments: One group is given the tested method, another is given a placebo, and often a third is given nothing. The editorial, written by Norbert Gleicher, MD, Vitaly Kushnir, MD, and David Barad, MD, MS, of the Center for Human Reproduction (CHR) in New York, notes fertility treatment is usually a race against a biological clock, and few patients would risk being unknowingly placed in the placebo group.
“… like clinical oncology, fertility treatments (especially in older women) are time dependent. Unlike clinical oncology, reproductive medicine, however, does not receive substantial financial research support from government or industry and, at least in the U.S., has, therefore, to be primarily funded via patient revenues. Given a 50 percent chance of receiving placebo, infertility patients are, understandably, reluctant to fund their own RCTs.”
The article is online now here: http://www.ncbi.nlm.nih.gov/pubmed/26282699
CHR researchers have authored countless published studies on fertility treatment, most recently the role of the FMR1 gene in predicting premature ovarian aging (POA), the use of the hormone DHEA in fertility treatment, differing results when using frozen or fresh donor egg cells, and how early egg retrieval may boost IVF chances in older patients.
These studies and more are found here: https://www.centerforhumanreprod.com/fertility/
These researchers are also clinicians who used their findings in fertility treatment, especially of women over 40: https://www.centerforhumanreprod.com/services/infertility-treatments/
About Center for Human Reproduction
The Center for Human Reproduction (CHR), located in New York City, is one of the world’s leading clinical and research centers in reproductive medicine and infertility. CHR has special expertise in treating women with low functional ovarian reserve, and pioneered many innovations that have become mainstays of infertility treatments worldwide. The study’s authors are available for further comments. Contact: 212-994-4400 x.4492